Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04456998 · ClinicalTrials.gov registry record · Phase 2
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
A Phase 2 study, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT04456998: Completed Phase 2 study, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
NCT04456998 is a Phase 2 study that has completed, run by GB002, Inc., a wholly owned subsidiary of Gossamer Bio. The registered enrollment target is 86 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04456998, a Phase 2 study, has completed, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.
Primary Outcome
PVR was evaluated using right heart catheterization (RHC).
Interventions
- DRUG Placebo
- DRUG GB002 (seralutinib)
- DEVICE Generic Dry Powder Inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
What the finished NCT04456998 record still lists
NCT04456998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04456998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04456998 about?
NCT04456998 is a clinical study titled "GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)". The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002...
What is the current status of trial NCT04456998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2020-11-12. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT04456998?
The interventions under investigation include: Placebo (DRUG), GB002 (seralutinib) (DRUG), Generic Dry Powder Inhaler (DEVICE).
Who is sponsoring clinical trial NCT04456998?
This trial is sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04456998's enrollment target sits among peer trials
86 812th of 2000 higher than 1,181 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI